Modality
mAb
MOA
PI3Ki
Target
ALK
Pathway
Neuroinflam
Meso
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
Aug 2019
→ Mar 2027
Phase 2Current
NCT04823126
1,182 pts·Meso
2024-05→2027-03·Active
NCT08519248
1,208 pts·Meso
2019-08→2025-02·Recruiting
2,390 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-051.1y agoPh2 Data· Meso
2027-03-1411mo awayPh2 Data· Meso
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2
Recruit…
P2
Active
Catalysts
Ph2 Data
2025-02-05 · 1.1y ago
Meso
Ph2 Data
2027-03-14 · 11mo away
Meso
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04823126 | Phase 2 | Meso | Active | 1182 | MRD |
| NCT08519248 | Phase 2 | Meso | Recruiting | 1208 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK |